<DOC>
	<DOCNO>NCT02646839</DOCNO>
	<brief_summary>This phase II , open-label , non-randomized , prospective study haploidentical transplantation use KIR-favorable donor child acute lymphoblastic leukemia ( ALL ) , acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) undergo allogeneic hematopoietic cell transplantation ( HCT ) . The relationship KIR2DL1 polymorphism survival child diseases undergoing approach allogeneic HCT study time frame also determine .</brief_summary>
	<brief_title>KIR Favorable Mismatched Haplo Transplant KIR Polymorphism ALL/AML/MDS Allo-HCT Children</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( HCT ) use match related unrelated donor well-accepted therapy child subtypes high-risk acute lymphoblastic leukemia ( ALL ) acute myeloid leukemia ( AML ) . For 40-50 % child match donor available , HCT approach vary center regional preference . HCT physicians France North America tend use human leukocyte antigen ( HLA ) -mismatched umbilical cord blood ( UCB ) , many large center Germany , part Asia , select US center favor HLA-haploidentical donor . Both approach improve significantly year variety reason , include well supportive care , cell process technique deliver consistently high-quality product , understand importance cell dose , key modification preparative immunosuppressive regimen . Both stem cell source offer distinct advantage disadvantage . T-cell-depleted haploidentical approach killer-cell immunoglobulin-like receptor ( KIR ) mismatch show lead less relapse patient AML13 , study , child ALL well . Disadvantages approach vulnerability viral infection requirement ex vivo T-cell depletion procedure currently IND . Cord blood readily available permissive degree HLA mismatch , current study show advantage survival compare match unrelated donor . Recently , randomize study one vs. two UCB unit base hypothesis decrease relapse incidence two unit result equivalent outcomes arm . Neutrophil engraftment immune recovery UCB transplantation relatively slow , lead high risk transplant-related mortality ; addition , large patient require two cord unit , dramatically increase cost stem cell procurement . No direct comparison two stem cell source ( haploidentical vs. UCB ) perform pediatric patient . Recently , investigator St. Jude Children 's Research Hospital publish excellent outcome use haploidentical donor graft deplete CD3+ cell ex vivo Miltenyi CliniMACS system . Their recent cohort AML ALL patient treat without total body irradiation ( TBI ) 5-year survival 88±15 % 19 consecutive patient , 17 survive long-term disease-free 2 patient die progressive leukemia . These result compare favorably 5-year survival 70±38 % transplantation use matched sibling 61±17 % match unrelated donor treat identical leukemia protocol indication transplantation define priori . These preliminary result suggest strategy use favorable KIR-mismatched haploidentical transplantation may lead good outcome alternative donor approach without side effect TBI . This protocol phase II trial seek establish feasibility preliminary outcome approach multi-institutional setting . In addition KIR-HLA matching , KIR allele polymorphism may also affect transplant outcomes.Recent data St. Jude show 312 pediatric HCTs , patient receive donor graft contain functionally strong KIR2DL1 allele arginine amino acid position 245 ( KIR2DL1-R245 ) good survival ( p=0.0028 ) low relapse rate ( p=0.022 ) receive donor graft contain functionally weak KIR2DL1 allele cysteine position ( KIR2DL1-C245 ) . Patients receive KIR2DL1-R245-positive graft HLA-C receptor-ligand mismatch best survival ( p=0.00004 ) low risk leukemia relapse ( p=0.005 ) . Thus , KIR-HLA match KIR allele polymorphism prognostic value . We attempt prospectively confirm result multicenter trial .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Biotin</mesh_term>
	<criteria>2.3.1 Inclusion Criteria Biology ( KIR2DL1 Polymorphisms/ALL MRD ) , Comparative Outcomes , Cost Effectiveness Trial 1 . Any patient ALL , AML , MDS deem eligible undergoes HCT participate center provide consent KIR2DL1 polymorphism , comparative outcome costeffectiveness portion trial . 2 . Any ALL patient undergo allogeneic HCT participate center eligible ALL deep sequence MRD portion trial . 2.3.2 Inclusion Criteria KIRfavorable Haploidentical Phase II trial : 1 . Age &lt; 22 year 2 . Disease disease status : ALL highrisk first remission ( &lt; 5 % blast morphology pretransplant ) meeting criterion transplant . Example CR1 indication : induction failure ( &gt; 5 % blast morphology postinduction BM ) , minimal residual disease great equal 1 % marrow blast morphology induction , minimal residual disease flow cytometry &gt; 0.01 % consolidation , hypodiploidy ( &lt; 44 chromosome ) , persistent recurrent cytogenetic molecular evidence disease therapy require additional therapy induction achieve remission ( e.g . persistent molecular BCRABL positivity ) . ALL second remission : Bcell ; early ( less equal 36 month initiation therapy ) BM relapse , late BM relapse MRD &gt; 0.1 % flow cytometry first induction therapy ; Tcell Ph+ BM relapse time ; early ( less 18 month initiation therapy ) isolate extramedullary relapse ( T Bcell ) Myelodysplastic syndrome ( MDS ) : Any 2001 WHO classification subtype ( Appendix I ) . RAEB2 patient may proceed directly transplant , may also receive induction chemotherapy transplant . Patients ≥20 % morphologic marrow blast require induction therapy reduce morphologic marrow blast 5 % transplant . Highrisk AML define monosomy 5 , del 5q , monosomy 7 , M6 , M7 , ( 6 ; 9 ) , FLT3ITD , patient great equal 25 % blast morphology induction , achieve CR 2 course therapy . Also , patient ≥ 0.1 % MRD evidence progressive extramedullary disease induction chemotherapy . AML second subsequent morphologic remission . 3 . Has receive prior allogeneic hematopoietic stem cell transplant . 4 . Does suitable HLAmatched sibling donor available stem cell donation . 5 . Does suitable match single antigen mismatch related unrelated donor available time ( noted search ) , patient 's best interest judge attend move forward stem cell transplantation rather wait unrelated donor become available ( refer subsection 2.5.1 detail ) . 6 . Has suitable HLA KIR favorable haploidentical match family member available stem cell donation . 7 . Karnofsky Index Lansky PlayPerformance Scale ≥ 60 % pretransplant evaluation . Karnofsky score must use patient &gt; 16 year age Lansky score patient &lt; 16 year age . 8 . Able give inform consent &gt; 18 year , legal guardian capable give informed consent &lt; 18 year . 9 . Adequate organ function ( within 4 week initiation preparative regimen ) , define : Pulmonary : FEV1 , FVC , correct DLCO must ≥ 50 % predict pulmonary function test ( PFTs ) . For child unable perform PFTs due age , criterion : evidence dyspnea rest need supplemental oxygen . Renal : Creatinine clearance radioisotope GFR ³ 70 mL/min/1.73 m2 serum creatinine base age/gender follow : Age Maximum Serum Creatinine ( mg/dL ) Male Female 1 &lt; 2 year 0.6 0.6 2 &lt; 6 year 0.8 0.8 6 &lt; 10 year 1 1 10 &lt; 13 year 1.2 1.2 13 &lt; 16 year 1.5 1.4 ≥ 16 year 1.7 1.4 The threshold creatinine value Table derive Schwartz formula estimate GFR utilize child length stature data publish CDC.45 Cardiac : Shortening fraction ≥ 27 % echocardiogram radionuclide scan ( MUGA ) ejection fraction ≥ 50 % echocardiogram radionuclide scan ( MUGA ) , choice test accord local standard care . Hepatic : \SGOT ( AST ) SGPT ( ALT ) &lt; 5 x upper limit normal ( ULN ) age . Conjugated bilirubin &lt; 2.5 mg/dL , unless attributable Gilbert 's Syndrome . 1 . Pregnant lactating female ineligible many medication use protocol could harmful unborn child infant . 2 . Patients HIV uncontrolled fungal , bacterial viral infection exclude . Patients history fungal disease induction therapy may proceed significant response antifungal therapy minimal evidence disease remain CT evaluation . 3 . Patients active CNS leukemia active site extramedullary disease time enrollment permit . Note : Those prior history CNS extramedullary disease , active disease time pretransplant workup , eligible . 4 . Patients genetic disorder ( generally marrow failure syndrome ) prone secondary AML/ALL know poor outcome eligible ( Fanconi Anemia , Kostmann Syndrome , Dyskeratosis Congenita , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Acute Myeloid Leukemia ( AML )</keyword>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>KIR-Favorable</keyword>
	<keyword>Haploidentical Transplantation</keyword>
	<keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
</DOC>